Almost in stealth mode the Swiss firm moves to begin a huge pivotal programme rivalling that of the IDO and IL-2 mechanisms.
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.